公开(公告)号：US20050048107A1

公开(公告)日：2005-03-03

申请号：US10731040

申请日：2003-12-08

申请人： Steven Sanders ,  Charles Ebert

发明人： Steven Sanders ,  Charles Ebert

IPC分类号： A61K9/02 ,  A61K9/00 ,  A61K9/06 ,  A61K9/10 ,  A61K9/16 ,  A61K9/22 ,  A61K9/52 ,  A61K9/70 ,  A61K31/216 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38 ,  A61P13/02 ,  A61P13/10 ,  A61P25/02 ,  A61K31/24

CPC分类号： A61K9/0024 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/1647 ,  A61K9/7061 ,  A61K31/216 ,  A61K47/10 ,  A61K47/14 ,  A61K47/38 ,  A61K2300/00

摘要： The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

摘要翻译： 本发明提供了用于奥昔布宁的组合物和方法，同时最小化与奥昔布宁治疗相关的不良药物经历的发生率和/或严重程度。 在一个方面，这些组合物和方法提供了较低的奥昔布宁代谢物的血浆浓度，例如N-去乙氧基丁啶，其被推定为至少部分地促成一些不良药物经历，同时保持足够的奥昔布宁血浆浓度以有益于 奥昔布宁治疗。 本发明还提供了符合以下特征的奥昔布宁及其代谢物的异构体，这些特征使不良药物经历的发生率和/或严重程度最小化，以及维持膀胱过度活动症的有益和有效治疗。

公开(公告)号：US20050048106A1

公开(公告)日：2005-03-03

申请号：US10731039

申请日：2003-12-08

申请人： Steven Sanders ,  Charles Ebert

发明人： Steven Sanders ,  Charles Ebert

IPC分类号： A61K9/02 ,  A61K9/00 ,  A61K9/06 ,  A61K9/10 ,  A61K9/16 ,  A61K9/22 ,  A61K9/52 ,  A61K9/70 ,  A61K31/216 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38 ,  A61P13/02 ,  A61P13/10 ,  A61P25/02 ,  A61K31/24

CPC分类号： A61K9/0024 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/1647 ,  A61K9/7061 ,  A61K31/216 ,  A61K47/10 ,  A61K47/14 ,  A61K47/38 ,  A61K2300/00

摘要： The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

公开(公告)号：US5925372A

公开(公告)日：1999-07-20

申请号：US725222

申请日：1991-06-26

申请人： Bret Berner ,  Charles Ebert ,  Gerard C. Mazzenga ,  John H. Otte

发明人： Bret Berner ,  Charles Ebert ,  Gerard C. Mazzenga ,  John H. Otte

IPC分类号： A61K9/70 ,  A61F13/02

CPC分类号： A61K9/7069 ,  A61K9/7084

摘要： A transdermal drug delivery system comprising(i) an occlusive, impermeable polymeric backing layer;(ii) a drug depot on one side thereof;(iii) a removable, occlusive covering layer over said drug depot; and(iv) an adhesive means by which said delivery system, absent said removable covering layer may be affixed to an intended patient;said drug depot containing a drug formulation comprising a transdermally administrable pharmaceutically acceptable pharmaceutically active agent or a precursor thereof, water and lower alkanol; said active agent or precursor thereof being present in a pharmaceutically effective amount; said lower alkanol and said water being present in a volume:volume ratio of from 30:70 up to less than 95:5 such that said lower alkanol, water and drug are delivered to a patient's skin, which patient has applied said system absent said removable covering layer to said patient's skin, in amounts that said drug is delivered in a transdermally administrable efficacious amount, said water has an activity at said patient's skin of about 0.4 to about 0.95 and said lower alkanol, at said patient's skin, has an activity of 0.3 to about 0.9, and wherein, once applied to said patient's skin, said lower alkanol has a flux from said system to said skin of at least 1500 mcg/cm.sup.2 /hr and through said skin of at least 1500 mcg/cm.sup.2 /hr.

摘要翻译： 一种透皮药物递送系统，其包括（i）封闭的，不可渗透的聚合物背衬层; （ii）其一侧的药剂库; （iii）所述药物库上的可移除的封闭覆盖层; 和（iv）粘合剂装置，其中没有所述可移除覆盖层的所述递送系统可以被固定到预期的患者身上; 所述药物贮库含有药物制剂，其包含透皮给药的药学上可接受的药物活性剂或其前体，水和低级链烷醇; 所述活性剂或其前体以药学上有效的量存在; 所述低级链烷醇和所述水以体积比为30:70至小于95:5存在，使得所述低级链烷醇，水和药物被递送至患者的皮肤，该患者应用所述系统不存在所述 所述药物以经皮可施用的有效量递送的量，所述水在所述患者皮肤上具有约0.4至约0.95的活性，并且所述低级烷醇在所述患者皮肤处具有活性 0.3至约0.9，并且其中一旦施用于所述患者皮肤，所述低级链烷醇具有从所述系统到所述皮肤的通量至少为1500mcg / cm 2 /小时，并且通过所述皮肤至少为1500mcg / cm 2 /小时 。

公开(公告)号：US4702513A

公开(公告)日：1987-10-27

申请号：US745852

申请日：1985-06-17

申请人： Charles Ebert ,  Jean L. Delcroix ,  Roland Majchrzak ,  Lothar Viertel

发明人： Charles Ebert ,  Jean L. Delcroix ,  Roland Majchrzak ,  Lothar Viertel

IPC分类号： B29C39/10 ,  B29K105/04 ,  B29L31/58 ,  B60J3/02

CPC分类号： B60J3/0265 ,  Y10T16/54038 ,  Y10T29/49885

摘要： A sun visor for automotive vehicles having a flat, generally rectangular, sun-visor body on which is provided in one corner a mounting bracket. The bracket may be formed by plastic injection molding and includes a mounting borehole for receiving one end region of a sun-visor shaft. The bracket supports a U-shaped leaf spring located in the borehole which radially clamps the end region of the sun-visor shaft. The arms of the spring are placed in recesses which are formed in the wall of the mounting borehole. The leaf spring is located within an insertion opening which is defined at one end of the mounting borehole. The insertion opening and the leaf spring located there are enclosed by a closure element.

摘要翻译： 一种用于机动车辆的遮阳板，其具有平坦的，大致矩形的遮阳板体，其一侧设有安装支架。 支架可以通过塑料注射成型形成，并且包括用于接收遮阳板轴的一个端部区域的安装孔。 支架支撑位于钻孔中的U形片簧，其径向地夹持遮阳板轴的端部区域。 弹簧的臂被放置在形成在安装钻孔的壁中的凹部中。 板簧位于安装钻孔的一端处的插入口内。 位于那里的插入开口和板簧被封闭元件包围。

公开(公告)号：US4610477A

公开(公告)日：1986-09-09

申请号：US735445

申请日：1985-05-17

申请人： Charles Ebert ,  Lothar Viertel ,  Rene Lecorvaisier ,  Joseph Menschaert

发明人： Charles Ebert ,  Lothar Viertel ,  Rene Lecorvaisier ,  Joseph Menschaert

IPC分类号： B29C39/10 ,  B29K105/04 ,  B29L31/58 ,  B60J3/02

CPC分类号： B60J3/0265 ,  Y10T16/54038 ,  Y10T29/49885

摘要： A sun visor for automotive vehicles with one or more mounting brackets which are formed within the body of the sun visor. The sun visor is a molded foam body rigidified by a reinforcing insert. The mounting brackets for the visor are preferably formed by plastic injection molding, and the visor body is formed by foaming over the insert and the brackets. The mounting brackets each have at least one insertion opening which accommodates a respective mounting shaft or pin for connecting the sun visor to the body of the vehicle. To prevent foaming material from entering into a bracket insertion opening during the production of the sun visor, the mounting brackets are formed with an integral extension surrounding the area of the insertion opening. The integral extension protrudes out of the region of the sun visor body being foamed. After the foaming step in the manufacturing of the sun visor is completed, the integral extension is removed from the mounting bracket. Then the mounting shaft is inserted into the insertion opening. The integral extension can also serve as an anchor for clamping the bracket in place during the foaming of the sun visor body.

摘要翻译： 一种用于具有一个或多个安装支架的汽车遮阳板，其形成在遮阳板的主体内。 遮阳板是由加强插入物硬化的模制泡沫体。 用于面罩的安装支架优选地通过塑料注射成型形成，并且通过在插入件和支架上发泡形成面罩主体。 安装支架各自具有至少一个插入开口，该插入开口容纳相应的安装轴或销，用于将遮阳板连接到车辆的车身。 为了防止在制造遮阳板时发泡材料进入支架插入口，安装托架形成有围绕插入开口的区域的整体延伸部。 整体延伸部分突出出遮阳板身体发泡的区域。 在遮阳板的制造中的发泡步骤完成之后，整体延伸部从安装支架上移开。 然后将安装轴插入插入口。 整体延伸部还可用作在太阳罩体发泡期间将支架夹紧在适当位置的锚固件。